PP 003
Alternative Names: PP-003Latest Information Update: 27 Feb 2024
Price :
$50 *
At a glance
- Originator Primary Peptides
- Class Antiparkinsonians; Peptides
- Mechanism of Action Alpha-synuclein degraders; Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 27 Feb 2024 PP 003 is still in preclinical trials for Parkinson's disease in Canada (Primary peptides pipeline, February 2024)
- 13 Jul 2021 PP 003 - Primary Peptides is available for licensing as of 07 Jul 2021. https://www.primarypeptides.com/partnerships.htm
- 07 Jul 2021 Preclinical studies in Parkinson's disease is still ongoing in Canada (Primary Peptides pipeline, July 2021)